A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP
-
- Yamashita Daisuke
- Department of Urology, Saiseikai Yokohamashi Nanbu Hospital
-
- Hanai Takahiro
- Department of Urology, Saiseikai Yokohamashi Nanbu Hospital
-
- Onuki Tatsuaki
- Department of Urology, Saiseikai Yokohamashi Nanbu Hospital
-
- Suzuki Kotaro
- Department of Urology, Saiseikai Yokohamashi Nanbu Hospital
-
- Nakayama Takashi
- Department of Pathology, Saiseikai Yokohamashi Nanbu Hospital
Bibliographic Information
- Other Title
-
- ミトタンの単独加療により長期生存を得た転移性副腎皮質癌の一例
Search this article
Description
<p>A 77-year-old man with a complaint of impaired consciousness was brought to our emergency department. The patient was referred to our department because of a huge retroperitoneal tumor and multiple pulmonary nodules detected on computed tomography. Owning to an abnormally high level of dehydroepiandrosterone sulfate, right adrenal cancer was suspected. Pathological examination of the retroperitoneal tumor by echo-guided pericutaneous biopsy revealed an adrenocortical carcinoma. Under the diagnosis of stage IV adrenocortical carcinoma, mitotane therapy was started in May 2013. We adjusted the mitotane dose on the basis of the clinical evidence and the adrenocorticotropic hormone and cortisol levels.</p><p>The tumors had increased in size after 2 months of the mitotane therapy. However, 2 months later, the tumor had significantly decreased in size. The treatment was continued for 53 months until he could no longer take medications orally, because of his advanced age, worse condition, and disuse syndrome.</p>
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 110 (1), 12-17, 2019-01-20
THE JAPANESE UROLOGICAL ASSOCIATION
